In Bid to Cut Costs, Teva to Halt R&D in Women's Health and Oncology

EZchip shares slide on revenue warnings; bourse staff face six-day workweek; Alcobra shares plummet after failed clinical trial.

Send in e-mailSend in e-mail
An employee collects newly manufactured pills at the tablet production plant at Teva Pharmaceutical headquarters in Jerusalem in 2011.Credit: Adam Reynolds/Bloomberg